"People started actively reaching out to us, especially over the holiday season in the winter," Brand told Insider.
"We don't expect that every compound will work for every patient, and realizing that those indications and mental health are very heterogeneous, we ultimately have to have multiple solutions," Brand said., which now has the largest market cap of any public psychedelics company. Compass is currently undergoing phase II trials to test COMP360, a synthetic psilocybin compound, for the treatment of treatment-resistant depression .
Back when the company first sought funding, Brand said that it was difficult to get institutional investors on board but that over time, investors began to warm up to the idea of psychedelic-based medications. While dozens of smaller startups have gone public on mostly Canadian exchanges over the past year, Atai has stayed private — raising more and more capital from venture capitalists and high net worth individuals to finance its drug development.
corporadelic is serious business. The medicalization of psychedelics may be Round 2 of its demise - Round 1 being counter-culture and Nixon-era drug policy. Public discourse on using the same broken system to deploy meds to treat mental health issues is woefully lacking.
BreelynnSayWHAA !!!!!
BrianGriffo All profits will go toward people in prison for selling drugs right?